Phase III study of pegcetacoplan for the treatment of focal segmental glomerulosclerosis (FSGS)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to an Apellis Pharmaceuticals, Inc.media release, company plans to initiate this trial 2H 2025.